Sustainability Plan

The Sustainability Plan is the tool used to share the Group’s future trajectory with its stakeholders: it represents an expression of the ambitions of the Recordati group and the commitments it wishes to prioritise in order to promote sustainable and responsible growth.

Growth and achievement of challenging business and sustainability goals are not incompatible: on the contrary, Recordati is convinced that responsible actions and the generation of shared value contribute to the long-term success of the Company.

Improving people’s health and quality of life is the basis of our mission: it is part of our DNA. Recordati’s People have always given their utmost every day to pursue this goal.

As emphasised by the World Health Organization (WHO), health is not merely the absence of disease or infirmity, but a state of complete physical, mental and social well-being. To improve health, it is therefore necessary to intervene on a number of determining factors, such as the social, physical and economic conditions under which people are born, live and work, including healthcare systems. In this context, in addition to institutions and governments, pharmaceutical companies must also develop strategies for the improvement of the healthcare system, in terms of availability, accessibility and quality of healthcare structures and the goods and services provided.

We are living in a rapidly changing world that often raises concerns about sustainability for future generations. The current scenario in which we live has led us to reflect deeply on the relationship between humanity and nature and on the importance of an overall balance: the well-being and health of people and the health of the planet are closely connected. We cannot be healthy in an unhealthy environment and with no health there is no wealth and no social equity.

With this systemic approach and in accordance with the 2030 Agenda for Sustainable Development priorities, we wish to contribute to supporting global development, promoting human well-being and protecting the environment.

 

We want to continue to do our part.

Patient Care

Our ambition We are open to partnering and dedicated to discovering and developing innovative, value-added products that improve quality of life and help people to enjoy longer, healthier and more productive lives. We wish to offer our patients fast, widespread and sustainable access to our products.

People Care

Our ambition We are committed to creating a safe and inclusive working environment where everyone can express their talents. Our Employees are our most important asset and, therefore, we recognise and value the role that each person plays in the success of our business. We aim to create shared value and positively contribute to sustainable development where we operate, aware of the importance of dialogue, collaboration and respect for the community.

Environmental Protection

Our ambition Improving human health is the cornerstone of our mission, but we are aware that the health and well-being of present and future generations and the health of our planet are closely interlinked. With this in mind, we want to take conscious action by working to preserve natural resources and biodiversity and contribute to the fight against climate change by minimising our environmental impact.

Responsible Sourcing

Our ambition We want to build relationships based on transparency and trust, sharing our values with suppliers and strategic partners. We are committed to constantly promoting respect for ethical, environmental and social aspects along the entire value chain.

Ethics and Integrity

Integrity is our founding value, and we lead by example.
The principles of honesty and transparency towards our Shareholders
and Stakeholders guide our daily actions.

The Sustainability Plan, defined in accordance with the materiality analysis, also highlights the contribution to the achievement of 10 of the 17 Sustainable Development Goals (SDGs) of the 2030 Agenda, the common goals signed by UN member states that outline a path of collaboration and responsibility to confront today’s complex challenges.

Process for the definition of the Sustainability Plan

The objectives of the CEO’s MBO scheme include the key social and environmental targets defined in the Sustainability Plan. Furthermore, responsibility for the achievement of the goals included in the Sustainability Plan is assigned to the representatives of the various departments involved, who have the resources, tools and know-how required for their implementation; the Management by Objectives (MBO) scheme integrates social and environmental objectives associated with the implementation of the Plan itself which are assigned to certain key management figures.

Ethics and Integrity – Future Targets [SDG 16]

Business ethics, integrity and anti-corruption

 

100% of Group employees involved in a two-year training programme on ethics, anticorruption, anti-bribery topics (2022 – 2023)

Patient Care – Future Targets [SDGs 3 – 9]1

Access to medicine and healthcare

 

Recordati believes that every single patient should have access to the best possible treatment.

 

In the field of rare diseases, the Group is committed to:

 

  • Continuing with Patient Assistance Program (PAP), Co-Pay Assistance Program (CAP) or similar programs aimed at providing assistance to patients who are eligible to receive financial support for products (2023)

 

  • Continuing to work closely with rare disease communities (including doctors, healthcare professionals, patients groups and families) to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases (2023)

 

  • Continuing to expand rare disease and orphan drugs innovation pipeline and R&D of new therapies (2023)

 

In the context of the Specialty & Primary Care Division, the Group is committed to:

 

  • Continuing to invest in our plant in Tunisia to be able to continue providing high-quality and affordable products servicing a broad range of therapeutic areas including low- and middle-income Countries (Tunisia, Sub-Saharan Africa) (2023).

 

Continue initiatives of product donations to organisations that collect and distribute pharmaceuticals to disadvantaged people (2023)




1. the table relating to the Group’s commitments to its patients shows only some of the targets. Commitments regarding quality, product safety, research and development, etc. are intrinsically related to the business and are thus ongoing. More details on the Group’s development plans are included in the Financial Statements.

People Care – Future Targets [SDGs 3 – 4 – 5 – 8]

Talent attraction and development

 

On the base of Key Value Driving Roles Matrix define Development and/or Retention Plan for the Successors, Key Resources, Talents and Critical Resources identified on the Matrix that at least once per year have to be discussed and agreed among the ELT (Executive Leadership Team) (2023).

 

Strengthening university engagement initiatives to promote the attraction of talent (2023)

 

Diversity and equal opportunities

 

Grant equal opportunities to all genders at all levels and progressively increase the percentage of women in Top and Senior management positions by promoting initiatives, including:

 

  • Recruit and promote employees who have both top skills and qualifications and reflect our focus on inclusion and diversity: from 2022 onwards, at least 40% of candidates short-listed for Top and Senior Management positions must be women and the internal personnel responsible for selecting new recruits and promoting employees must include at least one woman

 

  • Launch a mentorship initiative on D&I (2023)

 

Engagement

 

Seek employee feedback and measure evolution of engagement through the launch of an “Employee Opinion Survey” to all employees (2023).

 

Health, safety and well-being

 

Run an on-line driver safety training programme for all employees with a company car in order to encourage safe driving behaviors (2022- 2023)

 

Support for local communities

 

Continue to support the communities through solidarity, social and cultural initiatives aimed at promoting the growth and wellbeing of local communities (2023)

 

Launch of employee volunteering initiatives (2023)

Environmental Protection – Future Targets [SDGs 6 – 7 – 12 –13]

Climate action – renewable energy initiatives

 

100% renewable electricity purchased for our Group  production and packaging sites and annexed offices (2025)1

 

Finalization of feasibility studies for installing additional renewable energy production systems at the following plants: Italy (Campoverde), Ireland, Tunisia, Türkiye (2023).

 

Climate action – energy efficiency initiatives

 

Gradually replace traditional lighting systems with LED lights: complete replacement in the production department of the Milan plant by 2023

 

Climate action – other initiatives

 

Planting of about 11,250 trees in the Milan Metropolitan area (and maintenance for 5 years) through the support of the Forestami project for the three-year period 2021- 2023

 

Responsible waste management and circular economy initiatives

 

Continue with the analysis of possible new initiatives for the recovery and reuse of chemical raw materials used in production processes, and investigate further the possibility of recovering certain raw materials on a routine basis for which feasibility on an industrial scale has already been demonstrated (2022 – 2023)

 

Continue with the analysis of possible packaging solutions with lower environmental impact (2022- 2023)

 

1. Purchase of renewable electricity for plants located in countries where it is available.

Responsible Sourcing – Future Targets [SDGs 8 – 9]

Promote a responsible supply chain

 

  • Monitoring of suppliers on ESG aspects through assessment (desk audit) by an independent third party (EcoVadis): performance of 160 assessments (desk audits) by 20241

 

  • Engagement initiatives for suppliers that received lower scores in the assessment to promote and increase awareness of ESG aspects (2023)

For more information please see the Consolidated

Non-Financial Statement 2022

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
Corrine Porry
HR Business Partner, Rare Diseases

Corinne Porry is the Human Resource Business Partner of the Rare Diseases BU and is passionate about leadership development, creating thriving work environments, and helping people and organizations reaching their full potential.


She joined Recordati Rare Diseases in 2019, as the HR Lead of the EMEA region, before evolving on the current role in April 2025.


Corinne is a seasoned HR leader with widespread experience in multinational organizations, particularly within fast-paced and innovation-driven environments. Previously to Recordati, she held key HR leadership roles at MSD Vaccines, Sanofi Pasteur-MSD JV and Electronic Arts in the Entertainment Industry, where she supported major transformations, organizational designs and talent strategies. Her leadership style is grounded in empowering people, aligning teams around a shared purpose, and building inclusive, high-performing cultures. She began her career in HR management roles across diverse sectors including Retail, Biopharmaceuticals and Technology.


She holds a degree in Business Management from Rennes University and a master in Human Resources Management from the IAE of Aix-en-Provence. She is also a certified Executive Coach (ICF).

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

This website contains information about products that may not be available in all countries or may be available under different trademarks, for different indications, or in different doses. If you are a US resident please click the button below.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Ahora estás saliendo de este sitio, una página corporativa de Recordati Rare Diseases Iberia. Información para Profesionales Sanitarios.
Ahora estás saliendo de este sitio, una página corporativa de Recordati Rare Diseases Iberia. Información para Profesionales Sanitarios.

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

Réseau des Associations Vouées aux Troubles Sanguins Rares

The NRBDO is a pan Canadian coalition of not-for-profit organizations representing people with rare blood disorders and/or people with a chronic condition who are recipients of blood or blood products or their alternatives.

Lymphoma Canada (Lymphome Canada)

Lorsque l’on est confronté à un lymphome, on se sent vite dépassé. Nous sommes une communauté au sein de laquelle on peut parler de cette maladie qui est le cinquième cancer le plus fréquent au Canada.

Acromégalie Canada

Acromégalie Canada est un organisme à but non lucratif fondé en 2019 pour rassembler les Canadiens dont la vie a été touchée par l’acromégalie. Notre mission est de sensibiliser à l’acromégalie et au gigantisme par l’éducation tout en offrant un réseau de soutien aux patients et à leurs familles à travers le Canada.

Global Genes

Global Genes est une organisation éminente de lutte contre les maladies rares. Sa mission consiste à sensibiliser et éduquer la communauté mondiale ainsi qu’à établir des relations importantes et à fournir des ressources essentielles permettant aux défenseurs de cette cause de s’engager pour lutter contre leur maladie.

Regroupement Québécois des Maladies Orphelines

Par l’entremise de son Centre d’information et de ressources en maladies rares, la RQMO fournit des renseignements et du soutien aux professionnels de la santé, aux patients qui souffrent de maladies rares et orphelines ainsi qu’à leur famille.

Collège canadien de généticiens médicaux

Le CCMG est une organisation nationale canadienne qui aide ses membres, les gouvernements et le public en assurant la certification des personnes, en établissant des normes, en dispensant des formations, et en guidant la politique d’intérêt public.

National Urea Cycle Disorders Foundation (NUCDF, fondation nationale pour les troubles du cycle de l'urée)

La NUCDF (fondation nationale pour les troubles du cycle de l’urée) est dédiée à l’identification, le traitement et la guérison des troubles du cycle de l’urée.

Canadian Organization for Rare Disorders (CORD, organisation canadienne pour les maladies rares)

La CORD (organisation canadienne pour les maladies rares) est le réseau national canadien des organisations représentant toutes les personnes atteintes de maladies rares. La CORD s’engage en vue de promouvoir une politique et un système de santé qui répondent aux besoins des personnes atteintes de maladies rares.

The Garrod Association (l'association Garrod)

The Garrod Association (l’association Garrod) est un organisme canadien permanent à l’échelle nationale dédié à la coordination de la gestion de maladies métaboliques héréditaires.

Association canadienne de porphyrie

L’Association canadienne de porphyrie s’engage à promouvoir la santé en permettant aux personnes atteintes de porphyrie d’avoir accès à un service de conseil et à des informations pertinentes ainsi qu’à des programmes de soutien de groupe.

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Vous quittez Recordatirarediseases.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

Network of Rare Blood Disorder Organizations​

The NRBDO is a pan Canadian coalition of not-for-profit organizations representing people with rare blood disorders and/or people with a chronic condition who are recipients of blood or blood products or their alternatives.

Lymphoma Canada

Dealing with lymphoma can be overwhelming. We are community that helps people talk about and cope with the fifth most common cancer in Canada.

Acromegaly Canada

Acromegaly Canada is a not-for-profit established in 2019 to bring together Canadians whose lives have been touched by acromegaly. Our mission: to raise awareness of acromegaly and gigantism through education while providing a network of support for patients and their families across Canada.

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com

Regroupement Québécois des Maladies Orphelines

Through its Center for Information and Resources on Rare Diseases, RQMO provides information and support to health professionals and to patients with rare and orphan diseases and their families.

Canadian College of Medical Geneticists

CCMG is a national Canadian organization that serves its members, governments and the public by certifying individuals, establishing standards, providing education, and informing public policy.

National Urea Cycle Disorders Foundation

The NUCDF is dedicated to the identification, treatment and cure of urea cycle disorders.

Canadian Organization for Rare Disorders

CORD is Canada’s national network for organizations representing all those with rare disorders. CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders.

The Garrod Association

The Garrod Association is a permanent Canadian body at the national level for the coordination of the management of inherited metabolic disorders.

Global Genes

Global Genes is a leading rare disease advocacy organization. Their mission is to build awareness, educate the global community, and provide critical connections and resources that equip advocates to become activists for their disease.

Canadian Association for Porphyria

The Canadian Association for Porphyria is dedicated to promoting health by providing individuals with porphyria access to related counselling, information, and group support programs.

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
Elisabeth Bergmans
Head of Legal

Elisabeth holds a master degree in corporate and commercial law from the University of Maastricht, and has 17 years experience in the legal profession. She began her career at the Benelux law firm Loyens & Loeff in Amsterdam where she specialized in Private Equity, banking & finance and insolvency & restructuring.


Feeling the need to work closer to the business, Elisabeth then held different positions as Legal Counsel in various industries, such as pension fund investment management, sustainable energy and a private equity fund. In 2015 she joined Teva Pharmaceuticals’ European headquarters in Amsterdam, covering over the years different roles with growing responsibilities; in her last remit she was General Counsel EU Commercial, responsible for the European regional legal support of innovative medicines and commercial HQ activities. In 2021, Elisabeth moved to Milan and continued her activities from there.


In September 2024 she joined Recordati as Head of Legal RRD where she is responsible for the global legal support of the Rare Diseases B.U.

Davide Paganoni
Head of Oncology Franchise

Davide is a biologist with more than 20 years of experience in the Health Care business with a broad commercial experience that ranges from rare disease to OTC.  He joined RRD in 2022, with the acquisition of EUSA, where he used to be Head of Europe and Global Marketing. Prior to EUSA Davide had more experiences as General Manager for biotech and pharma companies as Amryt and Exeltis and before he gained a strong experience in rare disease and ultra-specialistic areas covering senior commercial roles in highly recognized companies like Alexion and Astra Zeneca.

Aziza Johnson
Head of Regulatory Affairs

Aziza Johnson holds a Bachelor of Pharmacy from the London School of Pharmacy and a master’s degree in law from the University of Leicester. She is also a certified Board member, having completed the ZHAW Board of Directors program.

 

Aziza has over 27 years of experience in regulatory affairs, clinical development, and scientific strategy across global pharmaceutical companies and regulatory agencies. She has worked on numerous drug development programs, from clinical trials to market launches, with expertise in orphan drug development, regulatory compliance, and pharmacovigilance. Her career spans leadership roles in both the public and private sectors, including positions at Pfizer and the Medicines and Healthcare products Regulatory Agency (MHRA), where she honed her skills in pharmaceutical regulation and drug approval processes. She also facilitated over 25 successful acquisitions, expanded into new markets, and secured numerous regulatory approvals across the FDA, EMA, MHRA, CFDA, TGA, ANVISA, and Health Canada.

 

In 2023, Aziza joined Recordati Rare Diseases as Head of Regulatory Affairs, where she oversees global regulatory affairs for treatments targeting rare diseases. She leads efforts to secure regulatory approvals across diverse markets, ensuring patients with unmet medical needs receive timely access to innovative therapies.

Francesco Palombi
Head of Finance

Francesco Palombi is an experienced finance executive with over 25 years of global experience across pharmaceuticals, energy, and luxury goods. He holds a Master’s degree in Business Management from the University Cattolica del Sacro Cuore of Milan.

 

He began his career in 1997 at Price Waterhouse and later moved to ENI S.p.A. and Snam Rete Gas, where he managed financial audits, reporting, and external financial statements. In 2005, he joined Roche, advancing to roles including Head of Accounting & Credit Management, Head of Finance & Manufacturing Controlling, and Head of Controlling & Business Analysis.

 

In 2015, he became CFO of Roche Thailand & New Markets, managing finance across multiple countries. He later served as Global Head of Finance for Supply Chain and Product Strategy at Roche, leading financial strategy for global supply chain and product management, before assuming his current role as Global Finance Head at Recordati Rare Diseases in 2022.

Juan-Carlos Gerena
Group Supply Chain Head

Juan Carlos Gerena is a results-driven executive with over 20 years of global experience in manufacturing, supply chain, and business development across diverse industries, including FMCG, pharmaceuticals (branded and generics), and commodities. He has a proven track record of leading large-scale transformations, driving operational excellence, and managing complex end-to-end supply chains in multicultural and international environments.


Currently, as VP of Global Supply Chain at Recordati Group, Juan Carlos oversees the supply chain strategy for both Specialty Pharma and Rare Diseases divisions. Previously, he led global supply operations for renowned organizations like Sobi, Teva Pharmaceuticals, Galderma, Novartis, and Mylan, achieving major milestones such as scaling supply chains to support global expansion, integrating supply networks post-acquisition, and optimizing S&OP processes. His expertise spans strategic sourcing, logistics, CDMO management, pipeline scalability, and digital transformation.


A dynamic leader with a focus on delivering value and operational efficiency, he also played pivotal roles at Shell Oil Products Europe and Unilever, managing complex logistics optimization projects, refinery supply chains, and innovative process development initiatives.


Juan Carlos holds an MBA from the University of Houston and a Bachelor of Science in Industrial Engineering from the University of the Philippines. A skilled communicator, he is fluent in Spanish, English, Italian, and Filipino, with a working knowledge of German. His global mindset, technical expertise, and cultural adaptability make him an influential leader in driving sustainable business growth and supply chain resilience.

Gianni Paniale
Human Resources Director

Gianni holds a degree in Business Administration from Bocconi University in Milan and has built a versatile career spanning management consulting and the pharmaceutical industry.  His professional journey began in 1989 at Proudfoot, a management consulting firm specialising in productivity and quality improvements. Gianni took on progressively senior roles, eventually leading international projects across Italy, France, Germany, the UK, and the Czech Republic.


In 1997, he joined Recordati, initially responsible for the Organisation department, he later assumed leadership of human resources for the commercial organisation in Italy. In 2004, Gianni played a pivotal role in Recordati’s international expansion, leading HR efforts for acquisitions, start-ups and the consolidation of local affiliates.


In 2022, he was appointed Human Resources Director for the Rare Diseases business unit, where he oversaw HR strategies for this specialised and impactful division of the Group. His career reflects a deep commitment to fostering organisational growth and development on both a domestic and global scale.

Georg Thies
Head of Endocrinology Franchise

Georg Thies holds a diploma in Biology and has over 30 years of experience in the pharmaceutical industry.

 

His career in pharma started in 1984 with an apprenticeship at AMERSHAM BUCHLER. He later studied Biology at the GEORG-AUGUST UNIVERSITY in Göttingen and participated in the ERASMUS Program at the KING’S COLLEGE in London.

 

After 2,5 years of civil service, he continued his career at ROCHE in 1995, progressing from Key Account Manager to roles in National and International Marketing for Oncology products.

In 2002 he joined Amgen in Switzerland as International Brand Director for Oncology and Business Unit Head Oncology Switzerland. From 2008 onwards he worked as a Country Director for Sweden.

In 2011, Georg returned to Switzerland, gaining experience in Project- and New Product Planning. He was appointed European Brand Director Cardiovascular in 2012 and European Franchise Director General Medicine in 2014, overseeing Cardiology, Nephrology, Osteoporosis, and Inflammation.

In 2016, he joined SHIRE/TAKEDA, eventually becoming the Global Commercial Executive Director and later VP Global Program Lead in Endocrinology. He concluded his tenure at TAKEDA as Global Commercial Lead Gastrointestinal.

Since August 2022, Georg has been the VP RECORDATI Rare Disease Franchise Head Endocrinology.

Luca Setti
Corporate Portfolio Management Director

Luca Setti is the Corporate Portfolio Management Director at Recordati Rare Diseases, where he is responsible for the evaluation of business development opportunities, and the strategic guidance for life cycle management and pipeline projects.


Luca joined Recordati in July 2020 as Corporate Portfolio Manager, playing a pivotal role in the latest transactions performed by the company in the rare disease space, and in the management of pipeline projects.


Prior to joining Recordati, Luca worked for 10+ years in the business and corporate development departments of Alfasigma and Chiesi Farmaceutici, where he led the completion of multiple asset deals and licensing transactions.


Luca holds a Master’s Degree in Management Engineering from the Politecnico di Milano

Caring for the planet

A clean environment is essential for people’s well-being: the health of the planet and the health of people are closely connected. The air we breathe, the water we drink and the climate we live in all have an impact on our wellbeing. Focusing on people’s health and being sustainable also means prioritising environmental protection while behaving responsibly towards future generations.

 

This is why we ensure we conduct business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the demands of our stakeholders.

Caring for our communities

Contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely an obligation or professional duty for Recordati but a moral imperative.

 

We believe that caring for the communities in which we’re a part is essential to help them develop and grow, and to foster a sense of pride and belonging among our people.

Our Culture

The Recordati culture is built on the pillars of entrepreneurship, purpose and belonging; all have been part of our company since our beginnings in a small pharmacy in Northern Italy almost 100 years ago.

 

At the heart of our culture are our people, who are focused on always doing the right thing in the right way. We work together – across businesses, borders, time zones and national cultures – to support patients around the world in unlocking the full potential of life.

 

We give people the opportunity to develop themselves and bring their own unique ideas and perspectives to the table. Our culture is one where people can truly be the best versions of themselves, are safe to speak up and empowered to make decisions and experiment, learning as they go.

Diversity & Inclusion

Diversity is at the heart of our business and we do not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics.

 

We work hard to create a safe and inclusive work environment, respecting everyone’s right to physical and psychological integrity, as well as freedom of opinion and association. We know that we each of us has a role to play in the success of Recordati and each of us is rewarded for the unique contributions we make, regardless of who we are or where we come from.

Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is the Managing Director and General Manager for EMEA at Recordati Rare Diseases, where he oversees the company’s business operations across Europe, the Middle East, and North Africa. In this role, he is responsible for a broad range of functions, including Commercial, Medical Affairs, Marketing, and Market Access as well as key enabling areas such as Human Resources, Finance, Legal, Compliance to support the business’s growth and success.

 

Luigi joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. During his tenure, he played a pivotal role in driving the expansion of the company’s rare disease portfolio, leading efforts in business development, strategic marketing, and the management of pipeline projects.

 

Prior to joining Recordati, Luigi held senior positions in business and corporate development at Chiesi Farmaceutici and Menarini Group, where he successfully led numerous high-impact asset deals and transactions.

Luigi holds a degree in Economics from the University of Florence and a Master’s in Business Innovation from the prestigious Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region

Bruno Parenti is VP of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific, and Russia. He started opening new markets in 2012, spearheading the expansion of operations around the globe including the direct entry in Japan, China, South Korea, Australia, Brazil, Colombia, Mexico, and Argentina. In the last 2 years, he has successfully integrated the oncology portfolio in the Region, with new launches expanding the access to these life changing therapies to more and more patients.

 

From 2019 to 2022 he has held the additional role of Head of Global Endocrinology, establishing the new HQ in Basel, building from scratch a dedicated organization and coordinating the global launch of Isturisa and the re-launch of Signifor.

 

Prior to these positions, he spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Mohamed Ladha
President and General Manager, North America

Mohamed Ladha is the President and General Manager at Recordati Rare Diseases where he is  responsible for the US and Canadian business. During his career,  Mohamed has held numerous leadership positions globally in hematology/oncology and specialty care to oversee business in the US, Canada, EU, China, Emerging Markets, and Japan.

 

Mohamed  joins Recordati Rare Diseases from Oncopeptides, where he was the General Manager and Executive Vice President for the US Region Business Unit. Prior to Oncopeptides, he served in a series of leadership positions of increasing responsibility at companies including Vertex Pharmaceuticals, Pfizer, Schering-Plough, Merck & Company, Hospira, ARIAD Pharmaceuticals, Takeda Oncology, and Tocagen. He started his career in basic science research focused in oncology at the Dana-Farber Cancer Institute.

 

Mohamed graduated from Hampshire College with a Bachelor of Arts degree. He also holds professional/graduate degrees from Harvard University’s Kennedy School of Government and Northwestern University’s Kellogg School of Management.

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.